Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC007549 | Panoply™ Human IL17RB Knockdown Stable Cell Line | Inquiry |
| CSC-SC007549 | Panoply™ Human IL17RB Over-expressing Stable Cell Line | Inquiry |
| CLOE-0559 | Human IL17RB(His) HEK293 Cell Lysate | Inquiry |
| CLOE-0560 | Human IL17RB(Fc) HEK293 Cell Lysate | Inquiry |
| CLOE-2286 | Mouse Il17rb(Fc) HEK293 Cell Lysate | Inquiry |
| CLOE-2289 | Mouse Il17rb HEK293 Cell Lysate | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD08015Z | Human IL17RB adenoviral particles | Inquiry |
| LV15354L | human IL17RB (NM_018725) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH318365 | shRNA set against Human IL17RB (NM_018725.3) | Inquiry |
| SHH318369 | shRNA set against Mouse IL17RB (NM_019583.3) | Inquiry |
| SHH318373 | shRNA set against Rat IL17RB (NM_001107290.1) | Inquiry |
| SHL171366 | shRNA set against Human IL17RB(NM_018725.3) | Inquiry |
| SHL171522 | shRNA set against Mouse Il17rb(NM_019583.3) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCL184781 | Human IL17Rb ORF clone(NM_018725.3) | Inquiry |
| CDCL184782 | Mouse IL17RB ORF clone(NM_019583.3) | Inquiry |
| CDFG002037 | Human IL17RB cDNA Clone(NM_018725.3) | Inquiry |
| CDFR007011 | Rat Il17rb cDNA Clone(NM_001107290.1) | Inquiry |
| MiUTR1H-04882 | IL17RB miRNA 3'UTR clone | Inquiry |
| MiUTR1M-05978 | IL17RB miRNA 3'UTR clone | Inquiry |
| CDCB156734 | Cynomolgus IL17RB ORF clone | Inquiry |
| CDCB187390 | Rabbit IL17RB ORF clone (XM_002713393.2) | Inquiry |
| CDCR374010 | Rat Il17rb ORF Clone(NM_001107290.1) | Inquiry |
The IL17RB gene encodes interleukin-17 receptor B (IL-17RB), a key member of the IL-17 receptor family. IL-17RB is a type I transmembrane protein with an extracellular region containing two characteristic fibronectin type III domains, a structural hallmark that distinguishes this receptor family from other cytokine receptors. While IL17RB shares homology with other family members, such as IL17RA, its ligand-binding specificity is distinct. IL-17RB binds with high affinity to two cytokines: IL-17B and IL-17E (also known as IL-25), with IL-25 being more widely studied due to its unique biological functions. Unlike IL-17A, which predominantly drives proinflammatory responses, IL-17RB signaling, especially via IL-25, predominantly initiates type 2 immune responses.
The primary biological role of IL17RB is as the dominant receptor for IL-25, acting as a central hub in type 2 immune responses. Type 2 immunity is crucial for defense against large extracellular parasites and forms the pathological basis of allergic inflammation. When IL-25 binds IL17RB on type 2 innate lymphoid cells (ILC2s), Th2 cells, basophils, and epithelial cells, it promotes the formation of a heterodimer with IL17RA, triggering a cytoplasmic signaling cascade. This pathway involves the adaptor protein Act1, recruitment of TNF receptor-associated factors (TRAFs), and activation of transcription factors NF-κB and AP-1, ultimately inducing production of type 2 cytokines such as IL-4, IL-5, and IL-13.
Figure 1. IL-17 Cytokine and Receptor Family. (Amatya N, et al., 2017)
IL-4 and IL-13 stimulate B cells to produce IgE and promote goblet cell hyperplasia and mucus overproduction.
IL-5 is essential for eosinophil activation, proliferation, and chemotaxis.
Thus, the IL17RB/IL-25 axis functions as an alert system, particularly in barrier tissues such as the lungs, skin, and gut, coordinating protective immune programs characterized by IgE elevation, eosinophilia, and mucus secretion. Beyond immune cells, IL17RB is also expressed in various non-immune cells, contributing to tissue repair and remodeling.
Clinically, IL17RB is primarily relevant in type 2 immune-mediated diseases, anti-parasitic immunity, and cancer:
Allergic diseases: In conditions such as asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps, the IL-25/IL17RB axis is a key driver. Elevated IL-25 in patient airways activates ILC2s and Th2 cells, leading to persistent IL-5 and IL-13 production, eosinophilic inflammation, airway hyperreactivity, and remodeling. Therapeutic strategies targeting IL-25 or IL17RB with monoclonal antibodies are being explored for severe eosinophilic asthma and atopic dermatitis, aiming to block the upstream cytokine cascade.
Anti-parasitic immunity: IL17RB signaling is crucial for clearance of intestinal helminths; pathway defects may impair effective protective immunity.
Cancer: IL17RB plays a context-dependent role. In certain solid tumors, such as breast and pancreatic cancers, IL17RB overexpression correlates with tumor invasion, metastasis, and poor prognosis, potentially via epithelial-mesenchymal transition or by stimulating tumor stemness through autocrine/paracrine signaling. Conversely, IL-25/IL17RB-driven type 2 responses in the tumor microenvironment may suppress anti-tumor type 1 immunity, indirectly facilitating immune evasion. Therefore, clinical strategies targeting IL17RB must be disease-context-specific: inhibiting its signaling in allergic diseases or tumors, but potentially enhancing it in parasitic infections.
References